Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Sanofi today and set a price target of EUR100.00. The company’s shares closed last Wednesday at $95.89. According to TipRanks.com, ...

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the ...

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

The American Lung Association is launching a new campaign to support and empower individuals living with chronic ...